The antibody RMT1-10 was shown to inhibit both Th1 and Th17 responses without a significant inhibitory effect on Th2 responses, Tregs or Bregs, as a low-activity antibody; treatment with RMT1-10, when administered after the development of autoimmunity and the progression of renal damage, suggesting that manipulation of TIM-1 may have potential therapeutic applications for LN. Here, HAVCR1 is linked to lobular neoplasia.